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Abstract
Background: To determine the effects of liposomal targeting of prednisolone phosphate (Lip-PLP) to synovial lining
macrophages on M1 and M2 polarization in vitro and during experimental arthritis.
Material and Methods: Experimental arthritis (antigen and immune complex induced) was elicited in mice and
prednisolone containing liposomes were given systemically. Synovium was investigated using microarray analysis, RT-PCR
and histology. Bone–marrow macrophages were stimulated towards M1 using LPS and IFNc before treatment by PLP-
liposomes. M1 and M2 markers were determined using RT-PCR.
Results: Microarray analysis of biopsies of inflamed synovium during antigen induced arthritis (AIA) showed an increased
M1 signature characterized by upregulation of IL-1b, IL-6 and FccRI starting from day 1 and lasting up until day 7 after
arthritis induction. The M2 signature remained low throughout the 7 day course of arthritis. Treatment of AIA with
intravenously delivered Lip-PLP strongly suppressed joint swelling and synovial infiltration whereas colloidal gold
containing liposomes exclusively targeted the macrophages within the inflamed synovial intima layer. In vitro studies
showed that Lip-PLP phagocytosed by M1 macrophages resulted in a suppression of the M1 phenotype and induction of
M2 markers (IL-10, TGF-b, IL-1RII, CD163, CD206 and Ym1). In vivo, Lip-PLP treatment strongly suppressed M1 markers (TNF-
a, IL-1b, IL-6, IL-12p40, iNOS, FccRI, Ciita and CD86) after local M1 activation of lining macrophages with LPS and IFN-c and
during experimental AIA and immune complex arthritis (ICA). In contrast, M2 markers were not significantly upregulated in
antigen-induced arthritis and down regulated in immune complex arthritis.
Conclusion: This study clearly shows that systemic treatment with PLP-liposomes selectively targets synovial lining
macrophages and inhibits M1 activation. In contrast to in vitro findings, PLP-liposomes do not cause a shift of synovial lining
macrophages towards M2.
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Introduction
Synovial lining macrophages play a crucial role in the onset and
maintenance of joint inflammation during arthritis [1,2]. Previous
studies have shown that their selective elimination with clodro-
nate-liposomes prior to induction or during established experi-
mental arthritis resulted in largely diminished synovial inflamma-
tion [3,4]. Although the activation stage of macrophages is very
versatile, various subpopulations have been defined reflecting
stadia of polarization. Classically activated macrophages are
induced by combined stimulation with lipopolysaccharide (LPS)
and interferon gamma (IFN-c) and these macrophages express a
unique set of genes giving rise to a pro-inflammatory phenotype.
Characteristically, these cells produce cytokines like TNF-a, IL-
1b, IL-6 and IL-12 in high amounts and upregulate MHC-II and
CD86, which facilitate antigen presentation [5,6]. The pro-
inflammatory activation state of macrophages can be further
enhanced through the high affinity receptor FccRI in response to
immune-complexes [7]. Furthermore, classically activated macro-
phages produce reactive oxygen species like nitric oxide (NO) via
nitric oxide synthase 2 (NOS2/iNOS) and stimulate T-cells
towards a Th1 or Th2 phenotype [8].
More recently, it has been described that macrophages can also
be alternatively activated in vitro, typically by IL-4, to induce a
macrophage with an anti-inflammatory phenotype [7]. These cells
express cytokines such as IL-10, with known anti-inflammatory
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properties and upregulate arginase 1 which inhibits NO produc-
tion. They also suppress antigen presentation molecules and T-cell
proliferation.
Classically activated, pro-inflammatory macrophages and alter-
natively activated, anti-inflammatory macrophages are now
generally referred to as M1 and M2 macrophages respectively.
More recently, several studies have indentified these subsets of
macrophages in animal models. Typically, M1 macrophages are
associated with infection [9], inflammation [10] and tissue injury
[11]. M2 macrophages are suppressed within these models, but
may have a role in the resolution of inflammation and in wound
repair [11].
Although glucocorticoids are known since long for their strong
inhibition of inflammation, their effect on subsets of macrophages
is only recently emerging. In vitro studies performed with human
and murine monocytes showed that glucocorticoids can drive
monocytes towards an M2-like phenotype characterized by
expression of CD163, a strong marker for M2 macrophages
[8,12]. In line with that, monocytes from healthy volunteers
showed upregulation of CD163 after relatively high doses of
intravenous glucocorticoids [13].
Glucocorticoids can be targeted to inflamed knee joints more
effectively by systemic intravenous injection within long circulating
‘stealth’ liposomes during experimental arthritis [8,14]. Recently,
we found that intravenous liposomal delivery of glucocorticoids
greatly improved its potency and a single injection strongly
inhibited knee joint inflammation in experimental arthritis [15–
17]. The strong effect on inhibition of joint inflammation may be
due to alteration of the macrophage phenotype within the lining
layer.
The aim of this study was to determine the effect of the
liposomally delivered glucocorticoid prednisolone phosphate (Lip-
PLP) on M1/M2 polarization of macrophages within the synovial
intima layer. For this, we studied gene expression of various M1
and M2 markers in the inflamed synovium during immune-
complex induced arthritis (ICA) and antigen-induced arthritis
(AIA). In ICA, the synovium is activated by immune complexes
whereas in AIA, activation is driven by both immune complexes
and T cells. As in the arthritis models the synovium is highly
infiltrated with leukocytes, we also studied the effect of Lip-PLP in
a model in which the synovium was activated towards an M1
phenotype with LPS and IFN-c by local injection into the knee
joint, which did not result in synovial infiltration. Additionally, we
studied the direct effect of Lip-PLP on M1 activated bone marrow
derived macrophages in vitro. Our results show that PLP-liposomes
target synovial intima cells and inhibit M1 macrophages but, in




All in vivo studies were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Dutch national legislation. The
protocol was approved by the local Committee on the Ethics of
Animal Experiments of the Radboud University Nijmegen (Permit
Number: RU-DEC 2006-182). All surgery was performed under
2,5% isoflurane with N2O/O2 anesthesia, and all efforts were
made to minimize suffering.
Liposome preparation
Liposomes were prepared as described previously [17], using a
lipid formulation of dipalmitoyl phosphatidylcholine (DPPC,
Lipoid GmbH, Ludwigshave, Germany), PEG 2000-distearoyl
phosphatidylethanolamine (DSPE) and cholesterol (Sigma Chem-
ical Co., Poole, UK) in a molar ratio of 1.85:0.15:1.0. These lipids
were dissolved in ethanol which was then evaporated from a
round-bottom flask to create a lipid film. The lipid film was
hydrated in a solution of 100 mg/ml prednisolone disodium
phosphate (PLP, Bufa, Uitgeest, the Netherlands) in water to
create liposomal PLP. Single unilamellar vesicles were obtained by
filtering the liposomal dispersion multiple times through polycar-
bonate filter membranes decreasing in pore diameter until the
liposomes had a mean diameter in the range of 90–110 nm with a
polydispersity of ,0.2. Mean particle size was determined by
dynamic light scattering with a Malvern 4700 system (Malvern
ltd., Malvern, UK). Unencapsulated PLP was removed by dialysis
against 0.9% phosphate buffered saline using Slide-A-Lyzer
dialysis cassettes with a molecular weight cut-off of 10,000 (Pierce,
Rockford, IL, USA). Encapsulation dose of PLP was determined
by extracting the aqueous phase from liposomal preparations with
chloroform. The aqueous phase after extraction was used for
determining the PLP content using high performance liquid
chromatography using a mobile phase acetonitril-water with pH of
2, connected to a UV-detector, which was set at 254 nm. Both
prednisolone and its phosphate ester could be measured in one
single run. Liposomal preparations contained around 5 mg/ml
PLP (slightly varying between batches) and an average of 60 mmol
phospholipid. Liposomes containing colloidal gold were prepared
in a similar manner except for the hydration step of the lipid film,
which was performed with a freshly prepared tetrachloroaurate
solution in citrate buffer. Colloidal gold was formed after sizing the
liposomes at 4uC and subsequently incubating the liposomes at
37uC. The non-encapsulated gold was removed by eluting the
preparation on a Sephacryl S1000-SF column (Pharmacia,
Uppsala, Sweden).
Animals
Mice (C57Bl/6, female) were purchased from Elevage-Janvier
(Le Genest Saint Isle, France) and were housed in the central
animal Lab in Nijmegen, The Netherlands in filter-top cages and
fed a standard diet and water ad libitum.
Antigen-induced arthritis (AIA)
AIA was induced as described previously [18]. Briefly, mice at
an age of 8–12 weeks were immunized with 100 mg methylated
bovine serum albumin (mBSA, Sigma-Aldrich, St Louis, USA),
emulsified in Freund’s complete adjuvant (Difco Laboratories,
Detroit, USA) which was injected into the flanks and the footpad
of the forelegs of the mice. Heat-killed Bordetella pertussis (RIVM,
Bilthoven, the Netherlands) was administered intraperitoneally as
an additional adjuvant. Two subcutaneous booster injections with
in total 50 mg mBSA/Freund’s complete adjuvant were given in
the neck region 1 week after the initial immunization. At week 3
after the initial immunization, AIA was induced by intra-articular
injection of 60 mg of mBSA in 6 ml saline into the knee joints. Mice
were treated at day 3 after induction of the AIA by intravenous
injection of liposomal PLP or free PLP (both 10 mg/kg), or saline
as a control. Mice were sacrificed at day 1 or day 5 after treatment
and tissues were isolated hereafter.
Immune-complex arthritis (ICA)
Immune-complex arthritis (ICA) was passively induced in knee
joints of mice as described previously [19] by direct intra-articular
injection of 3 mg of lysozyme in 6 ml saline into the knee joints of
mice that were intravenously injected anti-lysosyme antibodies
24 hours earlier. Mice were treated with intravenously injected
PLP Liposomes Inhibit M1 Macrophage Activation
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liposomal PLP (10 mg/kg) or saline at day 1 after induction of the
ICA. Twenty-four hour after treatment, mice were sacrificed and
tissues were isolated.
Local activation of the synovial lining in the knee joint
Naı¨ve mice were injected intra-articularly with 6 ml saline
containing interferon gamma (IFN-c, 100 ng) and Escherichia coli
lipopolysaccharide (LPS, 1 mg) to induce the M1 phenotype in
macrophages within the synovial lining. These mice and naı¨ve
control mice were treated 24 hours thereafter by intra-articular
injection of 6 ml of Lip-PLP (50 mg) or saline as a control. Twenty-
four hours after treatment, mice were sacrificed and tissues were
isolated.
Measurement of 99MTechnetium-uptake
Uptake of 99MTechnetium (Tc) was measured as described
previously [20] to determine the swelling of the knee joint that
occurs as a consequence of inflammation. Mice were sedated with
4.5% chloral hydrate and intraperitoneally injected with 20 mCi of
99MTc. After 30 minutes, the amount of radioactivity was
determined by external gamma counting. Knee joint swelling
was expressed as the ratio of 99MTc uptake in the right (R) and left
(L) knee joint of mice with an unilaterally induced arthritis in the
right knee joint. Right-left ratios .1.1 were taken to indicate
significant swelling of the right knee joint.
Sacrifice and tissue collection
Mice were sacrificed by cervical dislocation and arthritic knee
joints were isolated and fixed in 10% formalin for 4 days for
histological analysis. For RNA isolation, biopsies with a diameter
of 3 mm were punched out of the synovium from both the lateral
and medial side of the arthritic knee joints as described previously
[21] and were stored in liquid nitrogen until RNA isolation.
Histology
After fixation, total knee joints were decalcified in 5% formic
acid and thereafter embedded in paraffin. Standard frontal
sections of 7 mm were mounted on superfrost slides (Menzel-
Gla¨ser, Braunschweig, Germany) and stained with hematoxylin
and eosin (HE). The severity of joint inflammation was determined
as described previously [22], by scoring the amount of cellular
infiltration into the synovium using an arbitrary scale (0–3), for
three representative knee joint sections for each mouse (5 mice for
each treatment group). Scoring was performed in a blinded
manner by two independent observers: 0, no cells; 1, mild
cellularity; 2, moderate cellularity; 3, maximal cellularity.
Visualization of gold-liposomes
To visualize the uptake of gold-containing liposomes, knee joints
were removed from mice 24 hours after treatment with gold-
liposomes and were decalcified in ECTA/PVP (polyvinylpyrrilo-
dine) in TRIS buffer for 2 weeks. Knee joints were then frozen in
liquid nitrogen and sections were cut on a cryostat (Microm
HM500M, Waldorf, Germany) and mounted on Superfrost
microscopic slides (Menzel Gla¨ser, Germany). Silver enhancement
of colloidal gold was performed with Sigma silver enhancement kit
(Sigma, St. Louis, MO, USA) and terminated by incubating with a
0.5% sodium thiosulphate solution in distilled water. Sections were
counterstained with hematoxylin.
Macrophage culture
To obtain murine macrophages in vitro, bone marrow cells from
femoral shafts of C57Bl/6 mice were cultured in DMEM medium
(Invitrogen, Basel, Switzerland), supplemented with 10% FCS,
antibiotics and 10 ng/ml M-CSF (R&D systems). Medium was
refreshed every 3 days. Bone marrow macrophages were
incubated with 10 ng/ml IFN-c and 100 ng/ml Escherichia coli
LPS (Sigma-Aldrich) for 24 hours to induce M1 macrophages and
subsequently treated with 10 mg/ml Lip-PLP for another
24 hours. At day 7 of the macrophage culture (24 hours after
M1 induction and treatment), cells were submersed in Trizol
reagent (Invitrogen) for RNA isolation or scraped loose for flow
cytometry. Culture supernatant was stored at 220uC until
measurement of cytokine levels.
Measurement of cytokine levels
Cytokine levels of TNF-a, IL-1b, IL-6 and IL-12 were
measured in macrophage culture supernatant using Luminex
multianalyte technology, (Bio-Rad Laboratories, Hercules, USA)
according to the manufacturer’s instructions. Protein levels were
calculated from a standard curve of known cytokine concentra-
tions. Data analysis was performed using Bio-Plex Manager
software (Bio-Rad Laboratories).
Flow cytometry
Surface levels of CD86 were measured by flow cytometry. Cells
were counted, washed and incubated with PE-labeled rat anti-
mouse CD86 antibody (BD Pharmingen) for one hour. After
washing, labeling of the cells was measured by flow cytometry
using a FACSCalibur (BD Biosciences). Mean fluorescence
intensity (MFI) was corrected against a relevant isotype control
staining.
RNA isolation
RNA was isolated with a RNeasy kit (Qiagen, Venlo, the
Netherlands). Isolated nucleic acids were treated with DNAse
before being reverse transcribed into complementary DNA using
oligo (dT) primers and MMLV reverse transcriptase.
Microarray analysis
The microarray was performed as described previously [10],
using Affymetrix oligonucleotide arrays. Generation of biotiny-
lated complementary RNA and subsequent hybridization, washing
and staining of oligonucleotide arrays (Affymetrix, Santa Clara,
CA) were performed according to the Affymetrix Expression
Analysis Technical Manual for 1-cycle amplification. The arrays
were then scanned using a laser scanner (GeneChip Scanner;
Affymetrix) and analyzed using Affymetrix GeneChip Operating
Software (GCOS; version 1.4) according to the manufacturer’s
instructions. Gene expression relative to the house-keeping gene
GAPDH for each time point during AIA is presented as fold
change from expression levels of naı¨ve mice (means of 3 mice per
group).
Quantitative reverse transcriptase-polymerase chain
reaction (RT-PCR)
The RT-PCR was performed using the ABI Prism 7000
Sequence Detection system (Applied Biosystems) for quantification
with SYBR Green and melting curve analysis. Primers were
designed with Primer Express Version 2.0 (Applied Biosystems).
PCR conditions were as follows: 2 minutes at 50uC and
10 minutes at 95 50uC, followed by 40 cycles of 15 seconds at
95uC and 1 minute at 60uC. Primer concentrations were 300 nM.
All PCR’s were performed in a total volume of 20 ml. Data are
presented as expression levels relative to the house-keeping gene
GAPDH (means of 5 mice per group).
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Statistical analysis
Differences between treatment groups was tested for statistical
significance with Student’s t-test using GraphPad Prism 5 software.
Results are expressed as mean +/2 S.D.
Results
Inflamed synovium strongly expresses a dominant M1
signature during the course of antigen-induced arthritis
To characterize the expression of M1 and M2 markers in the
inflamed synovium during experimental arthritis, we isolated
messenger RNA from synovial biopsies in a standard manner [21]
at various time points (days 1, 3, 5 and 7) after induction of
antigen-induced arthritis (AIA). Gene expression in inflamed
synovium was determined by microarray as described earlier [10]
and compared with control synovium obtained from normal
mouse knee joints. Microarray analysis showed that various M1
markers (IL-1b, IL-6, FccRI and CD86) were strongly upregulated
at day 1 after induction of arthritis up to day 7 (Fig. 1A). The
majority of M2 markers (IL-1RII, CD163, CD206, Arg1 and
Ym1) were also somewhat upregulated during the course of
arthritis, although in lesser extent than the M1 markers, with the
exception of Arg1 and Ym1 which were especially high at day 1
after induction of AIA (Fig. 1B). Altogether though, this suggests a
shift towards a M1 signature in the inflamed synovium during
AIA.
Targeting the inflamed synovium with glucocorticoid
liposomes strongly suppresses experimental arthritis
Mice with established antigen-induced arthritis (AIA) expressing
a strong M1 signature at day 3, were treated with a single
intravenous injection of Lip-PLP (10 mg/kg) and showed a strong
suppression of joint swelling as measured by 99MTc-uptake by 74%
within 1 day when compared to saline controls and by 61% when
compared to free PLP treatment (Fig. 2A). At day 5 after
treatment, Lip-PLP had almost completely suppressed joint
swelling and histological examination of frontal knee joint sections
showed a mean suppression of the synovial infiltrate of 29% at day
1 and of 80% at day 5 after treatment (Fig. 2B+C).
Intravenous injection of gold-liposomes targets synovial
lining macrophages
To determine whether the Lip-PLP formulation is directly
targeted to macrophages in the synovial intima layer, we injected
liposomes containing colloidal gold intravenously into mice with
day 3 AIA. Silver enhancement staining of frontal sections of the
inflamed knee joint showed that at day 1 after injection, the gold-
laden liposomes were taken up by macrophages lying within the
synovial intima (Fig. 2D) suggesting that these liposomes leave the
bloodstream through the vessels lying just beneath the lining layer
and then become directly engulfed by the intima macrophages.
Type B synovial fibroblasts do not take up liposomes and may thus
be less affected [23].
Lip-PLP skews M1 macrophages towards an M2
phenotype in vitro
To study the direct effect of Lip-PLP on activated macrophages,
we first investigated whether liposomal PLP may alter M1
macrophages into an M2 phenotype in vitro. Bone marrow-derived
macrophages (BMMs) were stimulated towards an M1 type using
IFN-c (10 ng/ml) and LPS (100 ng/ml) for 24 hours and
subsequently treated with Lip-PLP for another 24 hours. Lipo-
somes were directly engulfed by non-stimulated macrophages and
M1 macrophages as measured by flow cytometry of fluorescently
labeled empty and PLP-liposomes (10, 100 and 500 mg/ml,
Fig. 3A). PLP-liposomes did not cause cell death as measured by
trypan blue uptake and by counting living cells and flow cytometry
of apoptotic cells with 7-AAD staining (data not shown).
Cytokine and membrane markers reflecting the polarization
status of M1 and M2 were measured by Luminex, flow cytometry
and QPCR. Treatment of M1 macrophages with Lip-PLP strongly
suppressed protein levels of M1 cytokines TNF-a (100%), IL-6
(100%), and IL-12 (91%) (Fig. 3B). Furthermore, Lip-PLP
significantly suppressed the M1 status as represented by surface
expression of CD86 by 82% (Fig. 3B).
To evaluate whether Lip-PLP treatment skews BMMs and M1
macrophages towards an M2 phenotype, we measured gene
expression of various generally accepted M2 markers. In BMMs
Lip-PLP treatment strongly upregulated mRNA levels of M2
associated genes IL-10 (7-fold) and CD163 (10-fold) (Fig. 3C). In
M1 macrophages Lip-PLP treatment strongly upregulated mRNA
levels of M2 associated genes IL-10 (3-fold), TGF-b (3-fold), IL-
1RII (14-fold), CD163 (undetected in M1 macrophages), CD206
(5-fold) and Ym1 (12-fold) (Fig. 3C), indicating that Lip-PLP is
capable of skewing both BMMs as well as M1 macrophages
towards an M2 phenotype.
Figure 1. Expression of M1 and M2 markers within the
inflamed synovium during AIA as determined by micro-array
analysis. Gene expression was determined at day 1, 3,5 and 7 after
induction of AIA. Fold increase of gene expression was compared to
synovium of naı¨ve mice. A: Expression of M1 markers (IL-1b, IL-6, FccRI
and CD86). B: Expression of M2 markers (IL-1RII, CD163, CD206, Arg1,
FIZZ1 and Ym1). Note that expression of M1 markers is highly
upregulated compared to M2 markers, with the exception of Arg1
and Ym1. Values are presented as the fold change in mean gene
expression levels (relative to GAPDH) from mean gene expression levels
of inflamed synovium (n = 8) compared to synovium drived from naı¨ve
mice (n = 3).
doi:10.1371/journal.pone.0054016.g001
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Glucocorticoid liposomes suppress M1 activation but do
not induce polarization of synovial lining macrophages
towards M2
Next, we investigated whether intra-articular injection of Lip-
PLP was able to alter M1 into an M2 signature in the synovial
lining of the murine knee joint. We first induced an M1 signature
in the lining macrophages by injection of LPS (1 mg) and IFN-c
(100 ng). At 24 hours thereafter, no significant cellular infiltrate of
the synovium was found (Fig. 4A). However, synovial biopsies
which included the intima layer showed high expression of mRNA
levels of M1 type cytokines TNF-a, IL-1b and IL-6 (13-, 16- and
16-fold, respectively) and of M1 markers iNOS, Ciita and CD86
(10-, 8- and 12-fold, respectively) when compared to naı¨ve
synovium (Fig. 4B). Injection of Lip-PLP (50 mg) into the M1
knee joint strongly suppressed all the upregulated M1 type genes to
levels not significantly different from those in naı¨ve mice when
measured at 24 hours thereafter (with the exception of iNOS). In
contrast, expression of M2 markers IL-10, IL-1RII, CD163,
CD206 and FIZZ1 was hardly changed by Lip-PLP treatment
(with the exception of Arg1) (Fig. 4B). These results suggest that
local injection of Lip-PLP inhibits M1 macrophages but does not
induce polarization towards M2 macrophages.
Systemic delivery of Lip-PLP during antigen induced
arthritis suppresses the M1 synovial macrophage without
altering the M2 phenotype within the inflamed synovium
To determine whether the M1 phenotype is suppressed in favor
of M2 by systemic treatment with PLP-liposomes during
experimental arthritis, we measured gene expression of various
M1 and M2 markers in the synovium at day 1 and day 5 after
systemic treatment with Lip-PLP of established AIA (day 3).
Treatment with PLP-liposomes resulted in a rapid and strong
down regulation of mRNA levels of M1 type cytokines TNF-a (8-
fold), IL-1b (55-fold), IL-6 (94-fold) and IL-12 (levels not detected)
at day 5 after treatment in the synovium (Fig. 5A). Additional
genes reflecting M1 activation like FccRI, Ciita and CD86, were
also significantly suppressed at day 5 after treatment (9-, 10- and 6-
fold, respectively), indicating a silencing of the M1 pattern by Lip-
PLP (Fig. 5B). In contrast to M1, expression of M2 markers IL-10,
IL-1RII, CD206, Arg1, CD163, FIZZ1 and Ym1 was not
significantly downregulated, even at day 5 after treatment (with
Figure 2. Liposomal targeting of PLP to the inflamed synovial lining strongly suppresses joint inflammation during AIA. A: Knee joint
swelling as measured by 99MTc-uptake is strongly suppressed after a single injection of Lip-PLP. B: Photomicrographs of frontal knee joint sections of
mice with AIA at day 5 after treatment and naı¨ve mice. Note that the inflammatory infiltrate is reduced in mice treated with Lip-PLP. Original
magnification6100, Asterisks points to synovial infiltrate, hash sign points to inflammatory exudates. C: Histological scoring of synovial infiltration at
day 1 and day 5 after systemic treatment with Lip-PLP or saline. D: Silver staining of frontal knee joint sections of mice with AIA, treated by
intravenous injection with gold-containing liposomes. Note that the silver staining of the gold particles is mostly observed within the synovial lining
cells (arrows). Mice were treated at day 3 after induction of AIA. Values are the mean of 8 mice per group. Original magnification6100; insert6400.
F = femur, JS = joint space. Statistical significance was determined by Student’s t-test. * = P,0.05 compared to saline treatment.
doi:10.1371/journal.pone.0054016.g002
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the exception of TGF-b), which does not point to a shift in
phenotype from M1 to M2 after treatment with Lip-PLP (Fig. 5B).
Systemic delivery of PLP-liposomes suppresses M1
activation during locally induced immune-complex
arthritis (ICA)
As antigen-induced arthritis is largely driven by T- and B-cells,
intravenous delivery of PLP-liposomes may alter systemic immu-
nity, which contributes to the rapid and strong effects on joint
inflammation. In order to investigate the direct effect of Lip-PLP
accumulation in the lining on the joint inflammation in more
detail, we finally tested a locally induced immune-complex arthritis
which is not dependent on T- or B-cell immunity. This arthritis
model is largely driven by macrophages in the knee joint in
response to local application of antibody-complexes in the joint
[19].
Similar to the AIA, systemic delivery of Lip-PLP inhibited
synovial infiltration at day 1 after injection (Fig. 6A) and
significantly suppressed M1 factors TNF-a (30-fold), IL-1b (230-
fold), IL-6 (116-fold), IL-12p40 (not detected anymore), FccRI (32-
fold), Ciita (18-fold) and CD86 (7-fold) (Fig. 6B). Treatment with
Lip-PLP even suppressed M2 factors and only CD163 expression
was somewhat upregulated by Lip-PLP (4-fold), suggesting that
Lip-PLP inhibits joint inflammation in ICA largely through
suppression of M1 macrophages.
Figure 3. Effect of Lip-PLP on M1 macrophages in vitro. Cells and supernatant of bone-marrow macrophages (BMM) and M1 macrophages
(stimulated with LPS and IFN-c for 24 hours) were obtained 24 hours after treatment with Lip-PLP or saline. A: Uptake of fluorescent liposomes by
BMM and M1 macrophages as measured by flow cytometry. Note that uptake of liposomes is dependent on the amount of liposomes but not on PLP
content. B: Protein levels of M1 cytokines TNF-a, IL-6 and IL-12 within the supernatant and surface expression of M1 marker CD86 as determined by
flow cytometry. C: Gene expression of M2 markers. RE = Relative Expression compared to values of GAPDH. Data are expressed as mean +/2 S.D.
UD = undetectable. Three independent experiments were performed. Statistical significance was determined by Student’s t-test. * = P,0.05,
** = P,0.01 compared to saline treatment.
doi:10.1371/journal.pone.0054016.g003
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Figure 4. Effect of Lip-PLP on M1 and M2 marker expression within the synovium after local M1 activation. Macrophages of the
synovial lining in the knee joints were activated towards M1 by intra-articular injection of LPS and IFN-c for 24 hours and were subsequently treated
by intra-articular injection of Lip-PLP or saline for 24 hours. A: Frontal knee joint sections of mice after local M1 activation and subsequent treatment
with Lip-PLP or saline and naı¨ve mice. B+C: Expression of M1 (B) and M2 (C) markers in the synovium. RE = Relative Expression compared to values of
GAPDH. Values represent the mean +/2 SD of eight mice. UD = undetectable. Statistical significance was determined by Student’s t-test. * = P,0.05,
** = P,0.01 compared to saline treatment.
doi:10.1371/journal.pone.0054016.g004
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Discussion
In earlier studies we found that a single systemic injection of
PLP-containing liposomes very efficiently downregulated joint
inflammation and destruction during AIA. In the present study we
studied the mechanism of this treatment on macrophage
polarization within the inflamed synovium of AIA. During the
7-day course of AIA, we found a strong upregulation of M1
markers in the synovium as measured with micro-array. A single
injection of PLP-liposomes strongly suppressed M1 signature in
favor of an M2 signature.
The effect of Lip-PLP on gene expression of M1 and M2
markers in the synovium was measured at 24 hours after
treatment. At that time-point, Lip-PLP treatment had caused a
strong suppression in joint swelling as measured by 99mTc uptake.
This rapid suppression of joint swelling is probably mediated by
down regulation of oxidants like superoxide radicals, reactive
Figure 5. Effect of Lip-PLP on M1 and M2 marker expression within the synovium during AIA. A: Expression of M1 markers. B: Expression
of M2 markers. Mice were treated by intravenous injection of Lip-PLP or saline at day 3 after induction of the AIA and synovial biopsies were obtained
at day 1 and day 5 after treatment. RE = Relative Expression compared to values of GAPDH. Data are expressed as mean +/2 SD of eight animals.
UD = undetectable. Statistical significance was determined by Student’s t-test. * = P,0.05, ** = P,0.01 compared to saline treatment.
doi:10.1371/journal.pone.0054016.g005
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Figure 6. Effect of Lip-PLP on M1 and M2 marker expression within the synovium during ICA. A: Photomicrographs of frontal knee joint
sections of mice with ICA at day 1 after treatment. B: Histological scoring of synovial infiltration mice with ICA at day 1 after treatment with saline or
Lip-PLP. C+D: Expression of M1 (C) and M2 (D) markers in the synovium during ICA. RE = Relative Expression compared to values of GAPDH. Mice were
treated at day 1 after induction of ICA and biopsies were obtained at day 1 after treatment. Data are expressed as mean +/2 SD of eight animals.
UD = undetectable. Statistical significance was determined by Student’s t-test. * = P,0.05, ** = P,0.01 compared to saline treatment.
doi:10.1371/journal.pone.0054016.g006
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oxygen species (ROS), nitrogen oxygen species (NO) or lipocortin/
vasocortin which largely drive vascular permeability and oedema
[24]. A recent study showed that corticosteroids are potent
inhibitors of superoxide radicals, ROS and NO species in
macrophages by reversing induction of iNOS mRNA, NOS
activity and NO levels [25]. Although joint swelling was already
significantly decreased at day 1 after Lip-PLP treatment, the
cellular infiltrate was not significantly changed within the knee
joint, thus forming good premises for comparison of genes within
the synovium.
PLP-liposomes may be taken up by monocytes and additionally
transported to the inflamed joint. However, after intravenous
injection of fluorescent PLP-liposomes, no fluorescent monocytes
were detected using FACS analysis (data not shown). The small
sized (100 nm) unilamellar liposomes used in our study are able to
migrate through the blood vessels in the inflamed knee joint which
lie just beneath the intimal lining layer. After crossing the
endothelium they are taken up by macrophages lying within the
thin synovial intimal layer. Macrophages efficiently bind and
phagocytose liposomes and in vitro no difference in uptake was
observed between macrophages with different activation status
(M1 versus normal) or between empty liposomes or liposomes
filled with glucocorticoids.
The uptake of Lip-PLP by activated macrophages in vitro
strongly suppresses M1 cytokines TNF-a, IL-6 and IL-12, but
stimulates expression of the anti-inflammatory cytokine IL-10.
This is in line with a study on activated monocytes by
Frankenberger et al., who reported that liposomal methylprednis-
olone suppressed TNF-a, but stimulated IL-10 production in
synergy with LPS activation of human monocytes [26]. Moreover,
IL-10 expression was elevated in our in vivo experiments compared
to naı¨ve mice, but was not suppressed by Lip-PLP in vitro. The high
IL-10 production could be an important contribution to the anti-
inflammatory effects of Lip-PLP as IL-10 and glucocorticoids can
work synergistically on the suppression of inflammation during
experimental arthritis [27].
In vitro uptake of Lip-PLP by M1 macrophages also suppresses
the M1 phenotype, as characterized by expression of CD86, and
either enhances or maintains expression of M2 genes, thereby
skewing these cells into a more M2-like character. This is in line
with other studies showing that free glucocorticoids induce M2-like
macrophages in human monocytes [12,28]. A recent study by
Varga et al. showed that mice treated with corticosteroids induced
an anti-inflammatory subset that resembled myeloid derived
suppressor cells [12]. Characteristic for M2 macrophages is the
expression of CD163, which is a well-recognized marker for anti-
inflammatory macrophages in humans and mice [12,29]. In the
present study, Lip-PLP caused an upregulation of CD163 in bone
marrow macrophages which was also found to be upregulated in
the synovium at day 1 after treatment of experimental arthritis
models ICA and AIA (although not statistically significant in the
latter). Therefore, this scavenging receptor provides a valuable
read-out to determine the anti-inflammatory effect of glucocorti-
coids on macrophages in models for inflammatory disease. PLP-
liposome uptake by M1 macrophages stimulated also other
mediators of M2 like TGF-b, IL-1RII and Ym1. Corticosteroids
have earlier been shown to be potent inducers of IL1RII in mouse
primary activated astrocytes [30].
In contrast with our in vitro data, Lip-PLP in vivo mainly
downregulated M1 but did not enhance the M2 signature. Also,
the effects of Lip-PLP on M1 and M2 signature in vivo in the
synovium were less pronounced. An explanation for that may be
that Lip-PLP that was exclusively taken up by a thin layer of lining
macrophages and not by macrophages lying at a more distant
location, may induce a more focal induction of M2 only within this
lining layer. The synovium used for M1/M2 investigation
included many macrophages not targeted by liposomes which
may dilute the ultimate results for shifting to M2. Earlier studies
have shown that synovial macrophages within this thin lining layer
drive propagation of synovial inflammation during antigen-
induced arthritis. Selective elimination of only lining macrophages
by local application of clodronate-containing liposomes in the knee
joint during established arthritis almost completely suppressed
synovial inflammation within a few days [4]. The lining
macrophages form the first layer that meets antigens released
from the cartilage or antigens reaching the joint via the blood.
The lining cells may control early joint inflammation by
upregulating suppressive molecules. During the first week of AIA,
M1 markers in the synovium are highly expressed whereas most
M2 markers remain low. Interestingly, a strong upregulation of
M2 markers Arg1 and Ym1 was observed during the first days of
the AIA which may regulate synovial inflammation during the first
phase of AIA. Both genes are specific markers for murine M2
macrophages [31]. Arginase 1 is an enzyme that competes with
iNOS for L-arginine and reduces the accumulation of reactive
oxygen species (ROS) [32]. The physiological role of Ym1 is not
clear but a role in promotion of cytokines is suggested [32].
Expression of Ym1 (but not Arg1) was raised by Lip-PLP
treatment of macrophages in vitro but also in the synovium after
1 day of treatment of AIA. Ym1 promotes Th2 cytokine
expression like IL-4 and IL-13 by inhibiting 12/15 lipoxygenase
[33]. These cytokines are expressed during AIA and have been
shown to strongly regulate synovial inflammation within this
model [34]. In direct response to IL-4 and IL-13, Ym1 is strongly
upregulated in murine macrophages in a STAT-6 dependent
manner [35] thereby forming a positive feedback loop which may
drive further Th2 differentiation.
Unlike Ym1, other mediators of M2 macrophages like IL-10,
TGF-b, IL-1RII, CD206 and FIZZ1 remained at the same level
and were not altered by Lip-PLP treatment whereas in contrast
M1 markers were strongly downregulated. Altogether this suggests
that there is no shift towards the M2 as the dominant phenotype
within the synovium after treatment with Lip-PLP.
In AIA, we have found evidence of favoring M2 by decreasing
M1 markers whereas in the ICA there is more an overall non-
specific decrease in M1 and M2 markers. An explanation for this
discrepancy may be that under in vivo conditions macrophages
which have taken up PLP-liposomes meet additional triggers like
ICs and T-cells which prevent an effective differentiation towards
an M2 status. ICs that drive joint inflammation in ICA can
stimulate macrophages into an M1 phenotype by binding to
activating FccR. In the AIA joint, apart from ICs also Th2 cells
meet synovial macrophages which produce cytokines like IL-4 and
IL-13 which may counteract the IC effects. Previous studies in our
lab have shown that overexpression of either IL-4 [36] or IL-13
[37] during ICA strongly diminished joint inflammation and
destruction, probably by differentiating macrophages into an M2
phenotype.
Treatment of arthritis with a single systemic injection of PLP-
liposomes has been shown to be much more effective than free
corticosteroids. This study clearly shows that selective targeting of
PLP-liposomes to synovial intimal macrophages strongly sup-
pressed M1 in both arthritis models whereas M2 was lower in ICA
and not altered in AIA. Suppression of the M1 signature by
liposomal PLP may drive the inflammatory status in the synovium
towards a more positive and more efficient treatment for patients
suffering from auto-immune disease.
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